Pacira BioSciences (PCRX) Revenue (2010 - 2026)

Pacira BioSciences has reported Revenue for 17 years, with the latest figure at $192.4 million in Q2 2026.

• On a quarterly basis, Revenue rose 6.24% year-over-year to $192.4 million in Q2 2026; TTM through Jun 2026 was $746.2 million, a 5.71% increase from a year earlier, with the FY2025 full-year figure at $726.4 million, up 3.63% from the prior year.
• Revenue was $192.4 million for Q2 2026 at Pacira BioSciences, up from $177.4 million in the prior quarter.
• The five-year high for Revenue was $196.9 million in Q4 2025, with the low at $158.0 million in Q1 2022.
• Average Revenue over 5 years is $174.4 million, with a median of $170.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Revenue surged 32.74% in 2022, then slipped 2.11% in 2023.
• Over 5 years, Revenue stood at $172.0 million in 2022, then climbed by 5.4% to $181.2 million in 2023, then gained by 3.32% to $187.3 million in 2024, then gained by 5.14% to $196.9 million in 2025, then declined by 2.27% to $192.4 million in 2026.
• The last three Revenue figures came in at $192.4 million (Q2 2026), $177.4 million (Q1 2026), and $196.9 million (Q4 2025), per Business Quant data.